← Evidence map

ArticleEClinicalMedicine2026

Safety, tolerability, and immunogenicity of SPVX02, a room temperature-stabilised tetanus-diphtheria vaccine, compared to two established tetanus-diphtheria booster vaccines: a multicentre, single-blind, randomised, first-in-human phase 1 trial in the UK.

Thomas A N Reed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Safety, tolerability, and immunogenicity of SPVX02, a room temperature-stabilised tetanus-diphtheria vaccine, compared to two established tetanus-diphtheria booster vaccines: a multicentre, single-blind, randomised, first-in-human phase 1 trial in the UK. | OpenQuestion